# A Study of Avutometinib for People With Solid Tumor Cancers

> **NCT06104488** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 23 (estimated)

## Conditions studied

- Refractory Cancer
- CNS Tumors
- CNS Tumor, Adult
- CNS Tumor, Childhood
- MAP Kinase Family Gene Mutation
- NF1
- Plexiform Neurofibroma
- Low-grade Glioma
- Optic Pathway Gliomas
- Neuroblastoma
- Primary Brain Tumor
- Solid Tumor
- Solid Tumor, Adult
- Solid Carcinoma
- Central Nervous System Tumor

## Interventions

- **DRUG:** Avutometinib

## Key facts

- **NCT ID:** NCT06104488
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-20
- **Primary completion:** 2029-10-20
- **Final completion:** 2029-10-20
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06104488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06104488, "A Study of Avutometinib for People With Solid Tumor Cancers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06104488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*